25Jun 2023
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

The study found that oral therapy orforglipron, a nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, effectively reduces weight in adults with obesity. In a 36-week trial with 272 participants, orforglipron led to a weight reduction ranging from 9.4% to 14.7%, with 46% to 75% of participants achieving a weight loss of at least 10%. The safety profile was consistent with injectable GLP-1 receptor agonists.

  • #family health

Like

Save

Share